Voruciclib is under clinical development by MEI Pharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Voruciclib’s likelihood of approval (LoA) and phase transition for Chronic Lymphocytic Leukemia (CLL) took place on 06 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Voruciclib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Voruciclib overview

Voruciclib (P-1446) is under development for the treatment of B-cell malignancies, refractory or relapsed chronic lymphoid leukemia and diffuse large B-cell lymphoma. As a third line therapy for follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia(CLL), diffuse large B-cell lymphoma (DLBCL) and relapsed/refractory acute myeloid leukemia. The drug candidate is administered orally and it acts by targeting Cdk4-D1, Cdk1-B and Cdk9-T. The drug candidate is developed based on Civo technology. It was also under development for the treatment of malignant melanoma, advanced refractory solid tumor, hematological malignancies, head and neck cancer, pancreatic cancer, mantle cell lymphoma and triple negative breast cancer.

MEI Pharma overview

MEI Pharma, formerly Marshall Edwards, develops drugs for the treatment of cancer. The company’s drug candidates include pracinostat, an oral histone deacetylase inhibitor, intended for the treatment of advanced hematological diseases including myelodysplastic syndrome; ME-344, a mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and Zandelisib (ME-401), an oral PI3K delta inhibitor for relapsed or refractory B-cell malignancies. The company also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor intended for the treatment of acute myeloid leukemia (AML) and B-cell malignancies through an agreement with Presage. MEI Pharma is headquartered in San Diego, California, the US.

Quick View Voruciclib LOA Data

Report Segments
  • Innovator
Drug Name
  • Voruciclib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: MEI Pharma
  • Originator: Piramal Enterprises
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.